hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06262555, orgStudyIdInfo id: TYGH111061, briefTitle: Novel Light Delivery Method for Performing Transbronchial Photodynamic Therapy for Peripheral Lung Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Taoyuan General Hospital, class: OTHER_GOV, descriptionModule briefSummary: This research aims to develop an innovative photodynamic therapy (PDT) for peripheral lung tumors. Current treatments involve surgery, chemotherapy, and radiation. Photodynamic therapy, using light and photosensitizing drugs, is promising but has limitations. Our team proposes using Lipiodol, a contrast agent, instilled into the trachea via bronchoscopy, surrounding the tumor. Preliminary pig model trials showed safety. Clinical trials, building on a U.S. study (NCT02916745), commenced in October 2021, treating three cases. Initial results suggest safety, but efficacy requires further investigation. Based on ongoing trials, we propose a phase I trial with multiple light treatments from different directions and an additional dose after 48 hours to assess safety and efficacy. This study will guide future clinical trials for optimal PDT dosage., conditionsModule conditions: Lung Cancer, conditions: Lung Cancer Metastatic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 3, type: ESTIMATED, armsInterventionsModule interventions name: Transbronchial PDT peripheral lung tumor ablation, outcomesModule primaryOutcomes measure: Technical Feasibility, primaryOutcomes measure: Technical Safety, secondaryOutcomes measure: Tumor remission rate, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taoyuan General Hospital, Ministry of Health and Welfare, status: RECRUITING, city: Taoyuan City, zip: 320, country: Taiwan, contacts name: Yei-San Hsieh, MD, role: CONTACT, phone: +886-975061108, email: yeisanh@gmail.com, contacts name: Yei-San Hsieh, Dr., role: PRINCIPAL_INVESTIGATOR, contacts name: Hwi-Lu Chang, Dr., role: SUB_INVESTIGATOR, geoPoint lat: 24.95233, lon: 121.20193, hasResults: False
protocolSection identificationModule nctId: NCT06262542, orgStudyIdInfo id: 111016, briefTitle: Efficacy and Safety of Chinese Herb Medicine-Moxibustion Therapy on Chemotherapy-Induced Leukopenia, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-13, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Taichung Armed Forces General Hospital, class: OTHER_GOV, descriptionModule briefSummary: Cancer is the second leading cause of death globally, with an estimated 9.6 million deaths in 2018, accounting for one-sixth of total deaths. The economic burden of cancer continues to rise globally, causing significant physiological, psychological, and economic pressures on individuals, families, communities, and healthcare systems. The toxic effects of chemotherapy, such as nausea, vomiting, decreased blood cells, fatigue, etc., can impair patients' function, activities, and quality of life. Chemotherapy-induced leukopenia (CIL), particularly low white blood cell counts (48.9%), is a major concern for cancer patients.Current conventional treatments primarily involve colony-stimulating factors (G-CSF and GM-CSF) to accelerate neutrophil recovery and regulate granulocyte production. However, G-CSF is costly and adds financial burden, and its use is restricted to cases meeting specific criteria. Additionally, rapid changes in patients' symptoms, weakness, and poor appetite may lead to swift deterioration of their condition, making it challenging to predict and prevent. Moreover, G-CSF has frequent side effects, including skin rash, liver function abnormalities, nausea, vomiting, fever, headache, fatigue, palpitations, and increased levels of ALP, LDH, and uric acid, with bone pain being the most common.Traditional Chinese Medicine (TCM) has been a long-standing medical practice in Eastern societies and is a legally recognized healthcare option in Taiwan, covered by national health insurance. TCM includes acupuncture, moxibustion, and Chinese herbal medicine, all of which have been researched for their potential in addressing chemotherapy-induced leukopenia., conditionsModule conditions: Cancer, Chemotherapy-induced Leukopenia, Chinese Herb Medicine-moxibustion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: moxibustion and Chinese herbal medicine group, outcomesModule primaryOutcomes measure: Track the number of white blood cells, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taichung Armed Force General Hospital, status: RECRUITING, city: Taichung, state: Taiping, zip: 411228, country: Taiwan, contacts name: ming huei cheng, role: CONTACT, phone: 0921059072, email: u9630091@cmu.edu.tw, geoPoint lat: 24.1469, lon: 120.6839, hasResults: False
protocolSection identificationModule nctId: NCT06262516, orgStudyIdInfo id: CASE2824, briefTitle: Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2027-01-01, completionDateStruct date: 2029-01-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Case Comprehensive Cancer Center, class: OTHER, descriptionModule briefSummary: The goal of this study is to conduct the first randomized-controlled trial to determine the oncologic efficacy of lymph node dissection in participants with upper tract urothelial cell carcinoma. The main questions it aims to answer are:* To determine oncologic outcomes, specifically 2-year recurrence-free survival* To determine other oncologic outcomes including treatment-free, cancer-specific and overall survival* To determine time to recurrence and recurrence patterns* To determine use of adjuvant therapies* To determine perioperative complicationsParticipants will undergo nephroureterectomy with or without lymph node dissection. Researchers will compare these two groups to determine the oncologic efficacy of performing lymph node dissection., conditionsModule conditions: Urothelial Carcinoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study is designed as a 1:1 two armed randomized-controlled trial., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 94, type: ESTIMATED, armsInterventionsModule interventions name: Nephroureterectomy, interventions name: Lymph Node Dissection, outcomesModule primaryOutcomes measure: Recurrence-free survival, secondaryOutcomes measure: Treatment-free survival, secondaryOutcomes measure: Cancer-specific survival, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Time to recurrence, secondaryOutcomes measure: Use of adjuvant therapies, secondaryOutcomes measure: Perioperative complications, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cleveland Clinic Glickman Urological and Kidney Institute, city: Cleveland, state: Ohio, zip: 44195, country: United States, contacts name: Mohamed Eltemamy, MD, role: CONTACT, phone: 216-444-5888, email: Eltemam@ccf.org, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06262503, orgStudyIdInfo id: P.T.REC/012/004810, briefTitle: the Influence of Virtual Reality Approach on Phantom Pain in Trans Tibial Amputation, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-02, completionDateStruct date: 2024-03, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: 1. To investigate the effect of Virtual reality (VR) on phantom limb pain in trans tibial amputation.2. To investigate the effect of Virtual reality (VR) on lower limb Function in trans tibial amputation.A sample size of 60 will be randomly allocated to two groups(30 in each group), by using computer-generated random number list method. Control group will receive conventional physiotherapy(TENS- Phantom exercises and mirroring exercise) for reducing phantom pain in trans -tibial amputation and the experimental group will receive conventional physiotherapy(TENS- Phantom exercises and mirroring exercise) and Virtual Reality for reducing phantom pain in trans -tibial amputation ., conditionsModule conditions: Phantom Pain Following Amputation of Lower Limb, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Group1:conventional physiotherapy for phantom Pain Group2:conventional physiotherapy and Virtual Reality for phantom Pain, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule interventions name: Virtual Reality, interventions name: Transcutaneous Electrical Nerve Stimulation (TENS), interventions name: Mirroring Therapy, interventions name: Phantom Exercises, outcomesModule primaryOutcomes measure: Pain Intensity Level, primaryOutcomes measure: Lower Extremity Functional, eligibilityModule sex: ALL, minimumAge: 18 Months, maximumAge: 75 Months, stdAges: CHILD, contactsLocationsModule locations facility: Faculty of Physical therapy, Cairo university, city: Giza, zip: 12613, country: Egypt, geoPoint lat: 30.00808, lon: 31.21093, hasResults: False
protocolSection identificationModule nctId: NCT06262490, orgStudyIdInfo id: P.T.REC/012/004765, briefTitle: Impact of Pelvic Floor Rehabilitation Combined With Ultrasound Therapy on Osteomyoarticular Symptoms in Chronic Perineal Pain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: The purpose of the study is to find out the effect of pelvic floor rehab combined with ultrasound have effect in chronic perineal pain subjects associated with osteomyoarticular symptoms ., conditionsModule conditions: Chronic Perineal Pain, conditions: Pelvic Floor Disorders, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Traditional ultrasound therapy, interventions name: Pelvic floor rehabilitation, outcomesModule primaryOutcomes measure: Assessment of osteomyoarticular symptoms, primaryOutcomes measure: Assessment of perineal pain intensity, secondaryOutcomes measure: Assessment of pelvic floor muscle strength, secondaryOutcomes measure: Assessment of pelvic floor muscle tightness, secondaryOutcomes measure: Assessment of lumbar spine mobility, eligibilityModule sex: FEMALE, minimumAge: 20 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Cairo University, city: Giza, country: Egypt, contacts name: Aya T- Allah M. Nabil, PhD student, role: CONTACT, phone: 01063028038, email: drayanabil1993@gmail.com, contacts name: Salwa M. El Badry, role: CONTACT, contacts name: Amel M. Yousef, Prof., role: PRINCIPAL_INVESTIGATOR, contacts name: Hazem S. Al-Ashmawy, Ass. Prof, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.00808, lon: 31.21093, hasResults: False
protocolSection identificationModule nctId: NCT06262477, orgStudyIdInfo id: NL-TCZ-12280, briefTitle: A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-02, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Biogen, class: INDUSTRY, descriptionModule briefSummary: The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and immunogenicity of BIIB800 and Actemra., conditionsModule conditions: Healthy Volunteer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: BIIB800, interventions name: Actemra, outcomesModule primaryOutcomes measure: Maximum Serum Concentration (Cmax) of Tocilizumab, primaryOutcomes measure: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab, primaryOutcomes measure: Area Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab, secondaryOutcomes measure: Time to Reach Cmax (Tmax) of BIIB800 and Tocilizumab, secondaryOutcomes measure: Apparent Total Body Clearance (CL/F) of BIIB800 and Tocilizumab, secondaryOutcomes measure: Apparent Terminal Half-Life (t1/2) of BIIB800 and Tocilizumab, secondaryOutcomes measure: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), secondaryOutcomes measure: Area Under the Effect-Time Curve (AUE) of Soluble Interleukin-6-Receptor (sIL-6R), secondaryOutcomes measure: Maximum Observed Effect (Emax) of sIL-6R, secondaryOutcomes measure: Time to Emax (tEmax) of sIL-6R, secondaryOutcomes measure: AUE of High Sensitive C-Reactive Protein (hsCRP), secondaryOutcomes measure: Minimum Observed Effect Emin of hsCRP, secondaryOutcomes measure: Time to Emin (tEmin) of hsCRP, secondaryOutcomes measure: Number of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAbs), secondaryOutcomes measure: Number of Participants With ADA Titers, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Fortrea Clinical Research Unit Inc., status: RECRUITING, city: Madison, state: Wisconsin, zip: 53704, country: United States, contacts role: CONTACT, phone: 608-210-5574, email: sarah.russell@fortrea.com, contacts name: Sarah Russell, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.07305, lon: -89.40123, hasResults: False
protocolSection identificationModule nctId: NCT06262464, orgStudyIdInfo id: 17.361/ 07.12.2023, briefTitle: An OCD Prevention Programme for at Risk Adults, acronym: ØCD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-09, primaryCompletionDateStruct date: 2024-03-29, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Babes-Bolyai University, class: OTHER, collaborators name: Romanian National Authority for Scientific Research, descriptionModule briefSummary: The main purpose of this randomised clinical trial is to test the efficacy of a prevention program for adult who are at risk of developing OCD, thus constituting a form of tertiary prevention., conditionsModule conditions: Obsessive-Compulsive Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Prevention, outcomesModule primaryOutcomes measure: Change from baseline in OCD symptoms on the OCI-R after the intervention, primaryOutcomes measure: Change from baseline in depressive symptoms on the PHQ-9 after the intervention, primaryOutcomes measure: Change from baseline in anxiety symptoms on the GAD-7 after the intervention, secondaryOutcomes measure: Change from baseline in experiential avoidance on the EAQ after the intervention, secondaryOutcomes measure: Change from baseline in cognitive distortions on the OBQ-44 after the intervention, secondaryOutcomes measure: Change from baseline in uncertainty intolerance on the IUS after the intervention, secondaryOutcomes measure: Change from baseline in resilience on the RSA after the intervention, otherOutcomes measure: Change from baseline in life quality on the WHOQOL-BREF after the intervention, otherOutcomes measure: Change from baseline in irrationality on the ATQ after the intervention, otherOutcomes measure: Change from baseline in global health on the GHQ-12 after the intervention, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Babes-Bolyai University, Faculty of Psychology and Educational Sciences, Department of Clinical Psychology and Psychotherapy, status: RECRUITING, city: Cluj-Napoca, zip: 400015, country: Romania, contacts name: Roxana AI Cardos, PhD Student, role: CONTACT, phone: 0040751477323, email: roxana.cardos@ubbcluj.ro, geoPoint lat: 46.76667, lon: 23.6, hasResults: False
protocolSection identificationModule nctId: NCT06262451, orgStudyIdInfo id: 20-30182, secondaryIdInfos id: 5R24AI118629, type: NIH, link: https://reporter.nih.gov/quickSearch/5R24AI118629, briefTitle: Fecal Microbiota Transplant National Registry, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-20, primaryCompletionDateStruct date: 2032-10, completionDateStruct date: 2032-10, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: University of California, San Francisco, class: OTHER, collaborators name: National Institute of Allergy and Infectious Diseases (NIAID), descriptionModule briefSummary: A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness. Neonates will not be enrolled at any site for this study. The study data will derive from patient and donors past and present medical records, research records, and records about phone calls made as part of this research. The patient data will also be used from the records on visits., conditionsModule conditions: Fecal Microbiota Transplant, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 10, type: ESTIMATED, outcomesModule primaryOutcomes measure: To assess short-term and long-term safety of FMT and other gut-related-microbiota products, secondaryOutcomes measure: To characterize effectiveness of FMT and other gut-related-microbiota products., secondaryOutcomes measure: To gather information on FMT practice in North America, secondaryOutcomes measure: To promote scientific investigation., secondaryOutcomes measure: To aid practitioners and sponsors in satisfying regulatory requirements, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, San Francisco, status: RECRUITING, city: San Francisco, state: California, zip: 94115, country: United States, contacts name: Rachael Leigh Delacruz, role: CONTACT, phone: 415-514-8087, email: rachaelleigh.delacruz@ucsf.edu, geoPoint lat: 37.77493, lon: -122.41942, hasResults: False
protocolSection identificationModule nctId: NCT06262425, orgStudyIdInfo id: ALC001NR004, briefTitle: rTMS Over S1 Enhance Motor Learning in Healthy People, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-20, primaryCompletionDateStruct date: 2025-06-15, completionDateStruct date: 2025-09-15, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Neuron, Spain, class: OTHER, descriptionModule briefSummary: The purpose of this study is to compare the effectiveness of different repetitive Transcranial Magnetic Stimulation protocols for enhancing motor learning in healthy peolple., conditionsModule conditions: Transcranial Magnetic Stimulation, conditions: Motor Learning, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 95, type: ESTIMATED, armsInterventionsModule interventions name: repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex, interventions name: repetitive Transcranial Magnetic Stimulation over primary motor cortex, interventions name: sham repetitive Transcranial Magnetic Stimulation, outcomesModule primaryOutcomes measure: Change in accuracy, secondaryOutcomes measure: Change in reaction time speed, secondaryOutcomes measure: Change in pegs placed in 30 seconds, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Neuron, status: RECRUITING, city: Madrid, zip: 28045, country: Spain, contacts name: Alfredo Lerín Calvo, PhD Student, role: CONTACT, phone: +34620187457, email: alfre_lerin@hotmail.com, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False